snowbrosgame| Watson Biological: As of April, the latest data released by the Chinese Center for Disease Control and Prevention show that the KP.2 COVID-19 variant has not spread widely in China

Tonghuashun (300033) Financial Research Center, May 13snowbrosgameSome investors asked Watson Biotech (300142)(300142). In early May this year, the World Health Organization had put KPsnowbrosgame.2 Subvarieties are listed as variants under monitoring. According to the latest disclosure by the Centers for Disease Control and Prevention (CDC)snowbrosgameThe main variant currently spreading in the United States is KP.snowbrosgame.2, among which the proportion of KP.2 infections has reached 25%. May I ask if the mRNA vaccine developed by your company is effective against the above variants?

The company replied, Hello, Dear Investor! As of April, the latest data released by the Chinese Center for Disease Control and Prevention show that the KP.2 COVID-19 variant has not spread widely in China. The KP.2 variant is a derivative of JN.1. From a technical perspective, previous infection and XBB vaccine vaccination should have a cross-effect on immune protection of the JN.1 variant. Thank you!

Tags:

Prev: pokerhandstexasholdem| Kangchen Pharmaceutical (01681.HK) plans to hold a board meeting on May 24 to review and approve the declaration of special dividends
Next: slotswincasinonodepositbonus| Vegetable oil 2409: Capital inflow of 431 million yuan, followed by methanol soybean meal